Abstract | PURPOSE: SETTING: Second University of Naples, Naples, Italy. DESIGN: Prospective non comparative case series study. METHODS: Patients with progressive keratoconus were examined, before and during a 6 months follow up after TE CXL, with a Pentacam, an Ocular Response Analyzer and an IOLMaster. Best corrected visual acuity (BCVA), refraction, corneal thinnest point ( CTP), keratometry readings at the keratoconus apex (Kmax), axial eye length (AL), corneal volume (CV) anterior chamber volume (ACV), anterior chamber depth (ACD), corneal hysteresis (CH) and corneal resistance factor (CRF) were evaluated. RESULTS: Thirty-six eyes of 36 patients with progressive keratoconus were analyzed. Six months after treatment there was a significant improvement in BCVA (p<0.01), no significant changes in refraction (p=0.57), CTP (p=0.07), Kmax (p=0.88), AL (p=0.07), CV (p=0.38), ACV (p=0.07), ACD (p=0.7), CH (p=0.1) and CRF (p=0.3). CONCLUSIONS: According to our results TE CXL stabilizes most of the patients with progressive keratoconus, without affecting in negative way the corneal elasticity.
|
Authors | Maddalena De Bernardo, Luigi Capasso, Antonia Tortori, Michele Lanza, Luisa Caliendo, Nicola Rosa |
Journal | Contact lens & anterior eye : the journal of the British Contact Lens Association
(Cont Lens Anterior Eye)
Vol. 37
Issue 6
Pg. 438-41
(Dec 2014)
ISSN: 1476-5411 [Electronic] England |
PMID | 25172670
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | Copyright © 2014 British Contact Lens Association. Published by Elsevier Ltd. All rights reserved. |
Chemical References |
- Photosensitizing Agents
- Riboflavin
|
Topics |
- Adolescent
- Adult
- Child
- Cornea
(pathology, physiopathology)
- Female
- Follow-Up Studies
- Humans
- Keratoconus
(diagnosis, physiopathology, therapy)
- Male
- Photosensitizing Agents
(therapeutic use)
- Refraction, Ocular
- Riboflavin
(therapeutic use)
- Treatment Outcome
- Ultraviolet Rays
- Ultraviolet Therapy
(methods)
|